European Alzheimer's drug market to grow to $4.78 billion by 2019, says F&S

The patent expiry of all four existing European Medicines Agency-approved drugs for Alzheimer's disease (AD) by 2015 is likely to cause a steep decline in the growth of the European AD medication market. However, the approval of next generation therapies that can delay disease progression and restore cognitive functions are expected to revive opportunities in the market from 2015 to 2018.

A new analysis from Frost & Sullivan, titled European Alzheimer's Disease Medication Market, estimates the market to earn $1.80 billion in 2012 and reach $4.78 billion in 2019, expanding at a compound annual growth rate (CAGR) of 15.1% from 2012-2019.

"Increasing R&D activity and a strong pipeline of disease modifying drugs bode well for market expansion," notes Frost & Sullivan senior research analyst Aiswariya Chidambaram. "Considerable unexplored opportunities and the commercial goldmine that is the AD medication market have motivated several pharmaceutical and biotechnology companies to invest in R&D, particularly targeting the moderate-to-severe patient group," she added.